<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        81-5286-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DACI
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DAPTOMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        372.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in <strong>Daci </strong>powder for solution for injection/infusion is daptomycin. Daptomycin is an antibacterial that can stop the growth of certain bacteria. Daptomycin is used in adults and in children and adolescents (age from 2 to 17 years) to treat infections of the skin and the tissues below the skin. It is also used in adults to treat infections in the tissues that line the inside of the heart (including heart valves) which are caused by a bacterium called <em>Staphyloccocus aureus </em>and to treat infections in the blood caused by the same bacterium when associated with skin or heart infection.</p><p>&nbsp;</p><p>Depending on the type of infection(s) that you have, your doctor may also prescribe other antibacterials while you are receiving treatment with Daptomycin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given </strong><strong>Daci</strong></p><p>&bull; if you are allergic to daptomycin or to sodium hydroxide or to any of the other ingredients of this medicine (listed in section 6).</p><p>If this applies to you, tell your doctor or nurse. If you think you may be allergic, ask your doctor or nurse for advice.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or nurse before you are given Daptomycin:</p><p>&bull; If you have, or have previously had kidney problems. Your doctor may need to change the dose of Daptomycin (see section 3 of this leaflet)</p><p>&bull; Occasionally, patients receiving Daptomycin may develop tender or aching muscles or muscle weakness (see section 4 of this leaflet for more information). If this happens tell your doctor. Your doctor will make sure you have a blood test and will advise whether or not to continue with Daptomycin. The symptoms generally go away within a few days of stopping Daptomycin</p><p>&bull; If you are very overweight. There is a possibility that your blood levels of Daptomycin could be higher than those found in persons of average weight and you may need careful monitoring in case of side effects.</p><p>&nbsp;</p><p>If any of these applies to you, tell your doctor or nurse before you are given Daptomycin.</p><p>&nbsp;</p><p><strong>Tell your doctor straight away if you develop any of the following symptoms: </strong></p><p>&bull; Serious, acute allergic reactions have been observed in patients treated with nearly all antibacterial agents, including Daptomycin. Tell a doctor or a nurse straight away if you experience symptoms suggestive of allergic reaction, such as wheezing, difficulty breathing, swelling of the face, neck and throat, rashes and hives, fever (see section 4 of this leaflet for more information)</p><p>&bull; Any unusual tingling or numbness of the hands or feet, loss of feeling or difficulties with movements. If this happens, tell your doctor who will decide whether you should continue the treatment</p><p>&bull; Diarrhea, especially if you notice blood or mucus, or if diarrhoea becomes severe or persistent</p><p>&bull; New or worsening fever, cough or difficulty breathing. These may be signs of a rare but serious lung disorder called eosinophilic pneumonia. Your doctor will check the condition of your lungs and decide whether or not you should continue Daptomycin treatment.</p><p>&nbsp;</p><p>Daptomycin may interfere with laboratory tests that measure how well your blood is clotting. The results can suggest poor blood clotting when, in fact, there is no problem. Therefore it is important that your doctor takes into account that you are receiving Daptomycin. Please inform your doctor that you are on treatment with Daptomycin.</p><p>&nbsp;</p><p>Your doctor will perform blood tests to monitor the health of your muscles both before you start treatment and frequently during treatment with Daptomycin.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>Daptomycin should not be administered to children below one year of age as studies in animals have indicated that this age group may experience severe side effects.</p><p>&nbsp;</p><p><strong>Use in elderly </strong></p><p>People over the age of 65 can be given the same dose as other adults, provided their kidneys are working well.</p><p>&nbsp;</p><p><strong>Other medicines and </strong><strong>Daci</strong></p><p>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. It is particularly important that you mention the following:</p><p>&bull; Medicines called statins or fibrates (to lower cholesterol) or ciclosporin (a medicinal product used in transplantation to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis or atopic dermatitis). It is possible that the risk of side effects affecting the muscles may be higher when any of these medicines (and some others that can affect muscles) is taken during treatment with Daptomycin. Your doctor may decide not to give you Daptomycin or to stop the other medicine for a while</p><p>&bull; Pain killing medicines called non-steroidal anti-inflammatory drugs (NSAIDs) or COX-2 inhibitors (e.g. celecoxib). These could interfere with the effects of Daptomycin in the kidney</p><p>&bull; Oral anti-coagulants (e.g. warfarin), which are medicines that prevent blood from clotting. It may be necessary for your doctor to monitor your blood clotting times.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>Daptomycin is not usually given to pregnant women. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine.</p><p>Do not breast-feed if you are receiving Daptomycin, because it may pass into your breast milk and could affect the baby.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Daptomycin has no known effects on the ability to drive or use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Daptomycin will usually be given to you by a doctor or a nurse.</p><p>&nbsp;</p><p><strong>Adults (18 years of age and above)</strong></p><p>The dose will depend on how much you weigh and the type of infection being treated. The usual dose for adults is 4 mg for every kilogram (kg) of body weight once daily for skin infections or 6 mg for every kg of body weight once daily for a heart infection or a blood infection associated with skin or heart infection. In adult patients, this dose is given directly into your blood stream (into a vein), either as an infusion lasting about 30 minutes or as an injection lasting about 2 minutes. The same dose is recommended in people aged over 65 years provided their kidneys are working well.</p><p>&nbsp;</p><p><strong>Children and adolescents (2 to 17 years of age) </strong></p><p>The dose for children and adolescents (2 to 17 years of age) being treated for skin infection will depend on the age of patient. The recommended doses based on age are shown in the table below:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:625px"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="LTR">Age group</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Dosage</p></td><td style="vertical-align:top"><p dir="LTR">Duration of treatment</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR">12 to 17 years</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">5 mg/kg once every 24 hours infused over 30 minutes</p></td><td style="vertical-align:top"><p dir="LTR">Up to 14 days</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">7 to 11 years</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Up to 14 days &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 mg/kg once every 24 hours &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infused over 30 minutes &nbsp;&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">2 to 6 years</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Up to 14 days &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 mg/kg once every 24 hours &nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;infused over 60 minutes</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><br />If your kidneys do not work well, you may receive Daptomycin less often, e.g. once every other day. If you are receiving dialysis, and your next dose of Daptomycin is due on a dialysis day, you will be usually given Daptomycin after the dialysis session.</p><p>&nbsp;</p><p>A course of treatment usually lasts for 1 to 2 weeks for skin infections. For blood or heart infections and skin infections your doctor will decide how long you should be treated.</p><p>Detailed instructions for use and handling are given at the end of the leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The most serious side effects are described below:</p><p>&nbsp;</p><p><strong>Very rare serious side effects </strong>(may affect up to 1 in 10,000 people)</p><p>A hypersensitivity reaction (serious allergic reaction including anaphylaxis, angioedema, drug rash with eosinophilia and systemic symptoms (DRESS)) has been reported in some cases during administration of Daptomycin. This serious allergic reaction needs immediate medical attention. Tell your doctor or nurse straight away if you experience any of the following symptoms:</p><p>&bull; chest pain or tightness</p><p>&bull; rash with blistering, sometimes affecting the mouth and genitals</p><p>&bull; swelling around throat</p><p>&bull; rapid or weak pulse</p><p>&bull; wheezing</p><p>&bull; fever</p><p>&bull; shivering or trembling</p><p>&bull; hot flushes</p><p>&bull; dizziness</p><p>&bull; fainting</p><p>&bull; metallic taste</p><p>Tell your doctor straight away if you experience unexplained muscle pain, tenderness, or weakness. In very rare cases (reported in less than 1 in every 10,000 patients), muscle problems can be serious, including muscle breakdown (rhabdomyolysis), which can result in kidney damage.</p><p>&nbsp;</p><p><strong>Serious side effects with frequency not known </strong>(frequency cannot be estimated from the available data)</p><p>A rare but potentially serious lung disorder called eosinophilic pneumonia has been reported in patients given Daptomycin, mostly after more than 2 weeks of treatment. The symptoms can include difficulty breathing, new or worsening cough, or new or worsening fever. If you experience these symptoms, tell your doctor or nurse straight away.</p><p>&nbsp;</p><p>If you experience raised or fluid-filled skin spots over a large area of your body, tell your doctor or nurse straight away.</p><p>&nbsp;</p><p>&nbsp;</p><p>The most frequently reported side effects are described below:</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>&bull; fungal infections such as thrush</p><p>&bull; urinary tract infection</p><p>&bull; decreased number of red blood cells (anaemia)</p><p>&bull; dizziness, anxiety, difficulty in sleeping</p><p>&bull; headache</p><p>&bull; fever, weakness (asthenia)</p><p>&bull; high or low blood pressure</p><p>&bull; constipation, abdominal pain</p><p>&bull; diarrhoea, feeling sick (nausea) or being sick (vomiting)</p><p>&bull; flatulence</p><p>&bull; abdominal swelling or bloating</p><p>&bull; skin rash or itching</p><p>&bull; pain, itchiness or redness at the site of infusion</p><p>&bull; pain in arms or legs</p><p>&bull; blood testing showing higher levels of liver enzymes or creatine phosphokinase (CPK)</p><p>&nbsp;</p><p>Other side effects which may occur following Daptomycin treatment are described below:</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&bull; blood disorders (e.g increased number of small blood particles called platelets, which may increase the tendency for blood clotting, or higher levels of certain types of white blood cells)</p><p>&bull; decreased appetite</p><p>&bull; tingling or numbness of the hands or feet, taste disturbance</p><p>&bull; trembling</p><p>&bull; changes in heart rhythm, flushes</p><p>&bull; indigestion (dyspepsia), inflammation of the tongue</p><p>&bull; itchy rash of skin</p><p>&bull; muscle pain, cramping, or weakness, inflammation of the muscles (myositis), joint pain</p><p>&bull; kidney problems</p><p>&bull; inflammation and irritation of the vagina</p><p>&bull; general pain or weakness, tiredness (fatigue)</p><p>&bull; blood test showing increased levels of blood sugar, serum creatinine, myoglobin, or lactate dehydrogenase (LDH), prolonged blood clotting time or imbalance of salts</p><p>&bull; itchy eyes.</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(may affect up to 1 in 1,000 people)</p><p>&bull; yellowing of the skin and eyes</p><p>&bull; prothrombin time prolonged</p><p>&nbsp;</p><p><strong>Frequency not known </strong>(frequency cannot be estimated from the available data)</p><p>Antibacterial-associated colitis, including pseudomembranous colitis (severe or persistent diarrhoea containing blood and/or mucus, associated with abdominal pain or fever), easy bruising, bleeding gums, or nosebleeds.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store in a refrigerator (2&deg;C-8&deg;C).</p><p>After reconstitution: Chemical and physical in-use stability of the reconstituted solution in the vial has been demonstrated for 12 hours at 25&deg;C and up to 48 hours at 2&deg;C-8&deg;C. Chemical and physical stability of the diluted solution in infusion bags is established as 12 hours at 25&deg;C or 24 hours at 2&deg;C-8&deg;C.</p><p>For the 30-minute intravenous infusion, the combined storage time (reconstituted solution in vial and diluted solution in infusion bag; see section 6.6) at 25&deg;C must not exceed 12 hours (or 24 at 2&deg;C-8&deg;C).</p><p>For the 2-minute intravenous injection, the storage time of the reconstituted solution in the vial (see section 6.6) at 25&deg;C must not exceed 12 hours (or 48 at 2&deg;C-8&deg;C).</p><p>However, from a microbiological point of view the product should be used immediately. No preservative or bacteriostatic agent is present in this product. If not used immediately, in-use storage times are the responsibility of the user and would not normally be longer than 24 hours at 2&deg;C-8&deg;C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.What </strong><strong>Daci</strong><strong> contains </strong></p><p>The active substance is daptomycin.</p><p>Daptomycin 500 mg: One vial of powder contains 500 mg daptomycin. One ml provides 50 mg of daptomycin after reconstitution with 10 ml of sodium chloride 9 mg/ml (0.9%) solution.</p><p>The other ingredient is sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Daptomycin powder for solution for injection/infusion is supplied as a pale yellow to light brown cake or powder in a glass vial. It is mixed with a solvent to form a liquid before it is administered. 
Daptomycin is available in packs containing 1 vial. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Manufacturer by:</strong></p><p>MS Pharma- Jordan for MS Pharma-Saudi.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jul-19
SPM190305


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1 ما هو </strong><strong>داسي وفيما يستخدم؟</strong></p><p dir="RTL">&nbsp;المادة الفعالة في دواء <strong>داسي </strong>المستخدم عبر الحقن أو المحاليل هي دابتومايسن. يعد دابتومايسن مضادا للبكتيريا حيث يمكنه إيقاف نمو أنواع محددة من البكتيريا. يستخدم دابتومايسن في البالغين والأطفال والمراهقين (من سن 2 إلى 17 سنة) وذلك من أجل علاج عدوى الجلد والأنسجة التي بأسفله.&nbsp; يستخدم هذا الدواء أيضا في المرضى البالغين من أجل علاج عدوى الأنسجة التي تغطي الجزء الداخلي من القلب (بما في ذلك صمامات القلب) والتي تتسبب فيها بكتيريا تسمى المكورات العنقودية الذهبية وأيضا من أجل علاج عدوى الدم الناتجة عن نفس البكتيريا عندما يصاحب ذلك وجود عدوى في الجلد أو القلب.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;قد يصف لك الطبيب مضادات حيوية أخرى أثناء تلقيك هذا الدواء، وذلك بناء على نوع العدوى التي لديك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;يجب عدم تناول </strong><strong>داسي في الحالات التالية:</strong></p><p dir="RTL">&nbsp;&bull; إذا كانت لديك حساسية مفرطة لمادة دابتومايسن أو هيدروكسيد الصوديوم أو لأي مكونات أخرى في هذا الدواء (من المكونات المذكورة في الفقرة 6).</p><p dir="RTL">يجب عليك إخبار الطبيب أو الممرضة إذا كانت أي من هذه الحالات تنطبق عليك. يجب استشارة الطبيب أو الممرضة إذا كنت تعتقد بأنك قد تعاني من الحساسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;قم بإبلاغ الطبيب أو الصيدلي أو الممرضة قبل تناول هذا الدواء، في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أو سبق وعانيت من أي مشكلة في الكلية. قد يحتاج الطبيب أن يغير جرعة دواء دابتومايسن (يرجى الاطلاع على الفقرة 3 من هذه النشرة الطبية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يعاني المرضى الذين يتناولون هذا الدواء في بعض الأحيان من ألم في العضلات أو ضعف في العضلات (يرجى الاطلاع على الفقرة 4 من هذه النشرة الطبية من أجل معلومات أكثر). يجب استشارة الطبيب إذا حدث ذلك. سيقوم الطبيب بالتأكد من إجراءك لبعض فحوصات الدم وبناء على نتيجة ذلك سينصحك بالمتابعة على هذا الدواء أو إيقافه.&nbsp; عادة ما تزول الأعراض في غضون عدة أيام بعد التوقف عن تناول دابتومايسن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض السمنة الزائدة. يُحتمل أن تكون مستويات دابتومايسن في الدم أعلى لديك مقارنة بالمرضى متوسطي الوزن، لذلك قد تحتاج إلى متابعة دقيقة في حالة حدوث أية أعراض جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إخبار الطبيب أو الممرضة قبل تناول هذا الدواء، إذا كانت أي من هذه الحالات تنطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;أخبر الطبيب على الفور عند ملاحظة أي من هذه الأعراض:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شاهدت حصول رد فعل تحسسي حاد وخطير في المرضى الذين تمت معالجتهم بما يقرب من جميع المضادات الحيوية بما فيهم دابتومايسن.&nbsp; يجب إبلاغ الطبيب أو الممرضة على الفور إذا كنت تعاني من أعراض تشير إلى إصابتك برد فعل تحسسي، مثل وجود أزيز في الصدر، صعوبة في التنفس، تورم في الوجه أو الرقبة أو الحلق، ظهور طفح جلدي وشرى، ارتفاع في درجة الحرارة (يرجى الاطلاع على الفقرة 4 من هذه النشرة الطبية من أجل معلومات أكثر).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي شعور غير معتاد بالتنميل أو وخز الإبر في اليد والقدم، أو فقدان الاحساس أو صعوبة في الحركة. إذا حدث أي من ذلك، فيجب إبلاغ الطبيب وهو سيُحدد إن كنت ستكمل على هذا الدواء أم لا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال، خاصة إذا لاحظت وجود دم أو مخاط فيه، أو إذا صار الإسهال شديدا أو مستمرا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في درجة الحرارة سواء كانت جديدة أو مُتفاقمة، بالإضافة إلى السُعال أو صعوبة في التنفس. يمكن أن تكون ذلك علامات للإصابة بمرض رئوي نادر ولكنه خطير، يسمى الالتهاب الرئوي اليوزيني. سيقوم الطبيب بفحص حالة الرئة، وسيقرر إذا كان من الأفضل لك الاستمرار على الدواء أو إيقافه.&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;يمكن أن يتداخل دابتومايسن مع نتائج التحاليل المعملية التي تقيس قدرة الدم على التجلط. يمكن أن تشير النتائج إلى ضعف في وظيفة تجلط الدم، ولكن في الواقع لا توجد ثمة مشكلة في ذلك.&nbsp; لذلك؛ فمن المهم أن يأخذ الطبيب في الحسبان أنك تتناول دواء دابتومايسن. يرجى إبلاغ الطبيب أنك تتناول دواء دابتومايسن.</p><p dir="RTL">&nbsp;سيقوم الطبيب بإجراء فحوصات للدم من أجل متابعة الحالة الصحية للعضلات قبل أن تبدأ العلاج بهذا الدواء، وأيضا على فترات زمنية متتالية أثناء تناولك هذا الدواء .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;الأطفال والمراهقين</strong></p><p dir="RTL">&nbsp;يجب عدم إعطاء دواء دابتومايسن إلى الأطفال الأصغر من عام واحد، لأن الدراسات السريرية على الحيوانات قد أشارت إلى احتمالية حدوث أعراض جانبية شديدة في هذه الفئة العمرية من المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;استخدام الدواء في المرضى كبار السن:</strong></p><p dir="RTL">&nbsp;يمكن إعطاء المرضى الذين تزيد أعمارهم عن 65 عاما نفس الجرعات التي تُعطى في حالات المرضى البالغين، بشرط أن تكون وظائف الكلية بحالة جيدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;تناول أدوية أخرى مع </strong><strong>داسي</strong></p><p dir="RTL">&nbsp;يجب إخبار الطبيب أو الممرضة إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر. من الضروري أن تذكر هذه الأدوية تحديدا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تسمى استاتين أو فيبرات (أدوية تعمل على خفض مستوى الكوليسترول) أو سايكلوسبورين (دواء يستخدم في عمليات زراعة الأعضاء من أجل منع حدوث رفض الجسم للعضو المزروع، كما يستخدم في أغراض أخرى أيضا مثل؛ علاج التهاب المفاصل الروماتيزمي أو التهاب الجلد التحسسي). من المحتمل أن تكون مخاطر الأعراض الجانبية التي تؤثر على العضلات أعلى عندما يتم تناول أي من هذه الأدوية (وبعض الأدوية الأخرى التي يمكن أن تؤثر على العضلات) أثناء العلاج باستخدام دابتومايسن. قد يقرر الطبيب عدم إعطاء دواء دابتومايسن أو إيقاف الأدوية الأخرى لفترة مؤقتة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المسكنة للألم وتسمى الأدوية غير الستيرويدية المضادة للالتهابات (NSAIDs) أو مثبطات إنزيم COX-2 (مثل سيليكوكسيب). يمكن أن تتداخل هذه الأدوية في تأثير دابتومايسن على الكلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التجلط المتناولة عبر الفم (مثل وارفارين) ، وهي أدوية تمنع تجلط / تخثر الدم. سيكون من المهم أن يتابع الطبيب زمن تجلط الدم لديك.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;لا يُعطى دواء دابتومايسن في المعتاد إلى السيدات الحوامل.&nbsp; يجب استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء في حالة السيدات الحوامل أو السيدات اللاتي تقمن بالرضاعة الطبيعية أو في حالات الاعتقاد بالحمل أو التخطيط لحدوث الحمل.</p><p dir="RTL">&nbsp;يجب التوقف عن الرضاعة الطبيعية أثناء تناول هذا الدواء لأنه يفرز في لبن الأم وقد يؤثر على الطفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;ليس للدواء أية تأثيرات معروفة على القدرة على القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيُعطى لك هذا الدواء دائما بواسطة الطبيب أو الممرضة.</p><p dir="RTL">&nbsp;سيعتمد مقدار الجرعة على الوزن ونوع العدوى التي يتم علاجها. الجرعة المعتادة للبالغين هي 4 ملغم لكل كيلوغرام من وزن الجسم، تعطى مرة واحدة يوميًا من أجل علاج العدوى الجلدية أو 6 ملغم لكل كيلوغرام من وزن الجسم مرة واحدة يوميًا للعدوى القلبية أو عدوى الدم المرتبطة بوجود عدوى في الجلد أو القلب. في المرضى البالغين، تُعطى هذه الجرعة مباشرة في مجرى الدم (في الوريد) ، إما عبر التنقيط بالمحلول الوريدي الذي يستمر حوالي 30 دقيقة أو عبر حقنة تؤخذ في حوالي دقيقتين. يوصى بالجرعة نفسها في الأشخاص الذين تزيد أعمارهم عن 65 عامًا بشرط أن تكون الكليتان تعمل بشكل جيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;الأطفال والمراهقين (من 2 إلى 17 عامًا)</strong></p><p dir="RTL">&nbsp;تعتمد جرعة الأطفال والمراهقين (من 2 إلى 17 عامًا)؛ الذين يتم علاجهم من الإصابة بعدوى في الجلد، على عُمر المريض. الجرعات الموصى بها بناء على العُمر موضحه في الجدول أدناه:</p><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الفئة العمرية</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>مدة العلاج</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">12 إلى 17 سنة</p></td><td style="vertical-align:top"><p dir="RTL">5 ملغم / كغم يعطى مرة كل 24 ساعة عبر التنقيط الوريدي لمدة 30 دقيقة</p></td><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">7 إلى 11 سنة</p></td><td style="vertical-align:top"><p dir="RTL">7 ملغم / كغم يعطى مرة كل 24 ساعة عبر التنقيط الوريدي لمدة 30 دقيقة</p></td><td style="vertical-align:top"><p dir="RTL"><strong>حتى 14 يوما</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">2 إلى 6 سنوات</p></td><td style="vertical-align:top"><p dir="RTL">9 ملغم / كغم يعطى مرة كل 24 ساعة عبر التنقيط الوريدي لمدة 60 دقيقة</p></td><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن الكليتان تعمل بشكل جيد، فقد تعطى دواء دابتومايسن بنسبة أقل من المعتاد، على سبيل المثال مرة كل يومين. إذا كنت تخضع للغسيل الكلوي وتصادف موعد جرعتك من دواء دابتومايسن مع يوم الغسيل الكلوي، فعادة ما ستُعطى دواء دابتومايسن بعد الانتهاء من جلسة الغسيل الكلوي.</p><p dir="RTL">&nbsp;تستمر دورة / جلسة العلاج بهذا الدواء إلى 1 أو 2 أسبوع من أجل علاج عدوى الجلد. سيقرر الطبيب المدة اللازمة لتناول هذا الدواء في حالات علاج عدوى الدم أو عدوى القلب مع الجلد.</p><p dir="RTL">&nbsp;ستجد ارشادات الاستخدام وطرق إعطاء الدواء في نهاية النشرة الدوائية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى.</p><p dir="RTL">&nbsp;الأعراض الجانبية الأكثر خطورة:</p><p dir="RTL">&nbsp;الأعراض الجانبية النادرة والخطيرة جدا (تؤثر في أقل من 1 إلى 10,000 شخص)</p><p dir="RTL">&nbsp;تم الإبلاغ عن إصابة بعض الحالات برد فعل تحسسي (رد فعل تحسسي خطير يشمل ذلك نوبة الإعوار &lt;الحساسية المفرطة&gt; والوذمة الوعائية والطفح الجلدي بسبب الدواء المصاحب لوجود زيادة الخلايا اليوزينية في الدم بالإضافة إلى أعراض جهازية) أثناء إعطائهم هذا الدواء.&nbsp; يتطلب رد الفعل التحسسي الخطير تدخل طبي فوري.&nbsp; أخبر الطبيب أو الممرضة على الفور عند ملاحظة أي من هذه الأعراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر أو ضيق في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مع ظهور بثور، قد يصيب الفم والأعضاء التناسلية في بعض الأحيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم حول الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة أو ضعف النبض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صوت أزيز الصدر عند التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش أو ارتجاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سخونة واحمرار الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مذاق معدني</p><p>&nbsp;</p><p dir="RTL">يجب إبلاغ الطبيب على الفور إذا شعرت بأي ألم غير طبيعي في العضلات، أو ألم عند لمسها أو ضعف فيها.&nbsp; في بعض الحالات النادرة (تم الإبلاغ غن حدوثها بنسبة أقل من 1 في كل 10.000 مريض) يمكن أن تكون المشاكل العضلية خطيرة بما في ذلك حدوث تكسر في العضلات (انحلال البربيدات / العضلات)، والذي قد يتسبب في حدوث فشل كلوي.</p><p dir="RTL">&nbsp;بعض الأعراض الجانبية الخطيرة التي لا يمكن تحديد نسبة تكرارها (لا يمكن تحديد نسبة تكرارها من البيانات المتاحة)</p><p dir="RTL">&nbsp;تم الإبلاغ غن إصابة بعض المرضى الذين يتناولون دواء دابتومايسن لمدة تتجاوز أسبوعين على الأغلب بمرض رئوي نادر جدا ولكنه يمكن أن يتحول لمرض خطير ، يسمى الالتهاب الرئوي اليوزيني. يمكن أن تشمل الأعراض المرضية وجود صعوبة في التنفس، سعال جديد أو متفاقم، ارتفاع في درجة الحرارة سواء كانت جديدة أو مُتفاقمة. يجب إبلاغ الطبيب أو الممرضة على الفور إذا كنت تعاني من هذه الأعراض.</p><p dir="RTL">&nbsp;إذا لاحظت وجود بقع مرتفعة عن الجلد أو بقع ممتلئة بالسوائل في جزء كبير من جسمك، فيجب أن تبلغ الطبيب أو الممرضة بشكل فوري.</p><p dir="RTL">&nbsp;الأعراض الجانبية الأكثر شيوعًا:</p><p dir="RTL">&nbsp;الأعراض الجانبية المألوفة (تؤثر في 1 من بين 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية مثل القلاع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الجهاز البولي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد كرات الدم الحمراء (فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار، قلق، صعوبة في النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في درجة الحرارة، ضعف (وهن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع / انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; امساك، ألم في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال، الشعور بالتعب (الغثيان) أو القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في البطن أو انتفاخ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي أو الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم، حكة أو احمرار في موضع المحلول الوريدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الذراعين أو القدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوضحت فحوصات الدم عن ارتفاع مستويات إنزيمات الكبد أو الكرياتينين الناقل للفوسفات (CPK)</p><p>&nbsp;</p><p dir="RTL">&nbsp;يمكن أن تحدث أعراض جانبية أخرى بعد تناول دواء دابتومايسن، وهي كالآتي:</p><p dir="RTL">&nbsp;الأعراض الجانبية غير المألوفة (تؤثر في 1 من بين 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في الدم (مثل زيادة عدد الصفائح الدموية والذي يمكن أن يزيد من نسبة تجلط الدم، أو زيادة عدد بعض الأنواع المحددة من خلايا الدم البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتنميل أو وخز الإبر في اليدين أو القدمين، بالإضافة إلى اضطراب في حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف / رعشة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في إيقاع ضربات القلب، احمرار الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم، التهاب في اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة وطفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات، تقلصات أو ضعف في العضلات، بالإضافة إلى التهاب في العضلات، ألم في المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وتهيج في المهبل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضعف بشكل عام، الشعور بالتعب (الإعياء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تظهر نتائج فحوصات الدم عن وجود زيادة في مستويات السكر في الدم أو الكرياتينين أو الميوغلوبين أو اللاكتات النازع للهيدروجين (LDH)، أو زيادة في وقت تجلط الدم أو عدم توازن في نسب أملاح الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالحكة في العين.</p><p>&nbsp;</p><p dir="RTL">&nbsp;الأعراض الجانبية النادرة (تؤثر في أقل من 1 إلى 1000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار في الجلد أو العين (يرقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في زمن البروثرومبين</p><p>&nbsp;</p><p dir="RTL">أعراض جانبية ذات معدل تكرار غير معروف (لا يمكن تحديد نسبة تكرار الأعراض من البيانات المتاحة):</p><p dir="RTL">&nbsp;التهاب القولون المرتبط بالمضاد الحيوي ويشمل التهاب القولون الغشائي الكاذب (إسهال شديد يحتوي على دم و / أو مخاط ويصاحبه وجود ألم في البطن أو ارتفاع في درجة الحرارة)، سهولة تكون الكدمات، نزيف من اللثة أو من الأنف.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">&nbsp;يحفظ الدواء في الثلاجة في درجة حرارة 2 - 8 درجة مئوية.</p><p dir="RTL">&nbsp;بعد إذابة مسحوق الدواء: الفترة التي يمكن للمحلول المُذاب أن يحافظ على استقرار صورته الكيميائية والفيزيائية في العبوة قد تم تحديدها بـ 12 ساعة في درجة حرارة 25 درجة مئوية وحتى 48 ساعة في درجة حرارة 2 - 8 درجة مئوية. كما تم تحديد الاستقرار الكيميائي والفيزيائي للمحلول المخفف في كيس التنقيط الوريدي بـ 12 ساعة في درجة حرارة 25 درجة مئوية أو 24 ساعة في درجة حرارة 2 - 8 درجة مئوية.</p><p dir="RTL">&nbsp;فيما يتعلق بالمحلول الوريدي الذي يُعطى في 30 دقيقة؛ فإن زمن التخزين الاجمالي للمحلول المذاب في العبوة والمحلول المخفف في كيس التنقيط الوريدي (يرجى الاطلاع على الفقرة 6.6) عند درجة حرارة 25 درجة مئوية يجب ألا يتجاوز 12 ساعة (أو 24 ساعة في درجة حرارة 2 - 8 درجة مئوية).</p><p dir="RTL">&nbsp;فيما يتعلق بالحقنة الوريدية التي تُعطى في 2 دقيقة؛ فإن زمن التخزين الاجمالي للمحلول المذاب في العبوة (يرجى الاطلاع على الفقرة 6.6) عند درجة حرارة 25 درجة مئوية يجب ألا يتجاوز 12 ساعة (أو 48 ساعة في درجة حرارة 2 - 8 درجة مئوية)..</p><p dir="RTL">&nbsp;وبرغم ذلك، فمن ناحية حفظ الدواء من أي عدوى ميكروبية، يجب استخدامه على الفور. لا يحتوي الدواء على مواد حافظة ولا على مواد مثبطة للبكتيريا.&nbsp; إذا لم يستخدم الدواء على الفور وهو في حالته الطبيعية وفي زمن التخزين المحدد له؛ والذي لا يتجاوز في الطبيعي أكثر من 24 ساعة عند درجة حرارة 2 - 8 درجة مئوية، فإن ذلك يعد مسؤولية المستخدم، إلا إذا تمت إذابته / تخفيفه في ظروف صحيحة وبصورة معقمة.</p><p dir="RTL">&nbsp;لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضحة على العبوة الكرتونية وعلى اللاصق بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">&nbsp;لا تستخدم هذا الدواء إذا لاحظت علامات مرئية بالعين تشير إلى وجود تلف.</p><p dir="RTL">&nbsp;لا تقم بإلقاء أية أدوية في مياه الصرف أو في النفايات المنزلية. وبدلاً عن ذلك قم باستشارة الصيدلي عن كيفية التخلص الآمن من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في المحافظة على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي محتويات داسي</strong></p><p dir="RTL">المادة الفعالة: دابتومايسن.</p><p dir="RTL">دابتومايسن 500 ملغم: يحتوي العبوة الواحد على 500 ملغم من دابتومايسن. يعطي 1 مل من المسحوق 50 ملغم من دابتومايسن بعد إذابته في 10 مل من محلول كلوريد الصوديوم 8 ملغم / مل (0.9%).</p><p dir="RTL">&nbsp;باقي المكونات: هيدروكسيد الصوديوم و والماء للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;ما هو شكل داسي وما هي محتويات العبوة:</strong></p><p dir="RTL">&nbsp;يتوفر مسحوق دابتومايسن المستخدم بعد إذابته في المحلول عبر الحقن أو التنقيط الوريدي في صورة مسحوق أصفر باهت إلى بني فاتح ويأتي في عبوة زجاجية. يأتي مخلوطا مع مادة مذيبة من أجل تحويله إلى صورة سائلة قبل إعطائه.</p><p dir="RTL">&nbsp;يأتي دابتومايسن في عبوة واحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية</p><p dir="RTL">الرياض ، المملكة العربية السعودية .</p><p dir="RTL">info-ksa@mspharma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:</strong></p><p dir="RTL">إم إس فارما &ndash; الأردن <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Jul-19
SPM190305

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Daci 500 mg Powder For Solution For Injection/Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 500 mg daptomycin.
For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection/infusion
A pale yellow to light brown .

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1 Therapeutic indications</strong></p><p>Daptomycin is indicated for the treatment of the following infections (see sections 4.4 and 5.1).</p><p>- Adult and paediatric (2 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).</p><p>- Adult patients with right-sided infective endocarditis (RIE) due to&nbsp;<em>Staphylococcus aureus</em>. It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice. See sections 4.4 and 5.1.</p><p>-Adult and pediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB)</p><p>- Adult patients with&nbsp;<em>Staphylococcus aureus</em>&nbsp;bacteraemia (SAB) when associated with RIE or with cSSTI.</p><p>In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in pediatric patients, use in bacteraemia should be associat-ed with cSSTI.</p><p>Daptomycin is active against Gram positive bacteria only (see section 5.1). In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Daptomycin should be coadministered with appropriate antibacterial agent(s).</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p>Children under 1 year of age should not be given Daptomycin due to the potential risk of effects on muscular, neuromuscular and/or nervous system (either peripheral or central); such effects have been observed in neonatal dogs.</p><p>There is one characteristic of Daptomycin which affects susceptibility testing namely that Daptomycin requires an appropriate concentration of free calcium (Ca2+) ions for accurate assessment of its activity in vitro.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical studies in patients employed infusion of daptomycin over 30 minutes. There is no clinical experience in patients with the administration of daptomycin as an injection over 2 minutes. This mode of administration was only studied in healthy subjects. However, when compared with the same doses given as intravenous infusions over 30 minutes there were no clinically important differences in the pharmacokinetics and safety profile of daptomycin (see also sections 4.8 and 5.2).</p><p><u>Posology</u></p><p><em><u>Adults</u></em></p><p>- cSSTI without concurrent<em>&nbsp;Staphylococcus aureus</em>&nbsp;bacteraemia: Daptomycin 4 mg/kg is administered once every 24 hours for 7-14 days or until the infection is resolved (see section 5.1).</p><p>- cSSTI with concurrent&nbsp;<em>Staphylococcus aureus</em>&nbsp;bacteraemia: Daptomycin 6 mg/kg is administered once every 24 hours. See below for dose adjustments in patients with renal impairment. The duration of therapy may need to be longer than 14 days in accordance with the perceived risk of complications in the individual patient.</p><p>- Known or suspected right-sided infective endocarditis due to&nbsp;<em>Staphylococcus aureus</em>: Daptomycin 6 mg/kg is administered once every 24 hours. See below for dose adjustments in patients with renal impairment. The duration of therapy should be in accordance with available official recommendations.</p><p>Daptomycin is administered intravenously in 0.9% sodium chloride (see section 6.6). Daptomycin should not be used more frequently than once a day.</p><p><em>Renal impairment</em></p><p>Daptomycin is eliminated primarily by the kidney.</p><p>Due to limited clinical experience (see table and footnotes below) Daptomycin should only be used in patients with any degree of renal impairment (CrCl &lt; 80 ml/min) when it is considered that the expected clinical benefit outweighs the potential risk. The response to treatment, renal function and creatine phosphokinase (CPK) levels should be closely monitored in all patients with any degree of renal impairment (see also sections 4.4 and 5.2).</p><p>Dose adjustments in patients with renal impairment by indication and creatinine clearance</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Indication for use</p></td><td style="vertical-align:top"><p>Creatinine clearance</p></td><td style="vertical-align:top"><p>Dose recommendation</p></td><td style="vertical-align:top"><p>Comments</p></td></tr><tr><td style="vertical-align:top"><p>cSSTI without SAB</p><p>bacteraemia</p></td><td style="vertical-align:top"><p>&ge; 30 ml/min</p></td><td style="vertical-align:top"><p>4 mg/kg once daily</p></td><td style="vertical-align:top"><p>See section 5.1</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&lt; 30 ml/min</p></td><td style="vertical-align:top"><p>4 mg/kg every 48 hours</p></td><td style="vertical-align:top"><p>(1, 2)</p></td></tr><tr><td style="vertical-align:top"><p>RIE or cSSTI associated with&nbsp;<em>S. aureus bacteraemia</em></p></td><td style="vertical-align:top"><p>&ge; 30 ml/min</p></td><td style="vertical-align:top"><p>6 mg/kg once daily</p></td><td style="vertical-align:top"><p>See section 5.1</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&lt; 30 ml/min</p></td><td style="vertical-align:top"><p>6 mg/kg every 48 hours</p></td><td style="vertical-align:top"><p>(1, 2)</p></td></tr></tbody></table><p>(1) The safety and efficacy of the dose interval adjustment have not been evaluated in controlled clinical trials and the recommendation is based on pharmacokinetic studies and modelling results (see sections 4.4 and 5.2).</p><p>(2) The same dose adjustments, which are based on pharmacokinetic data in volunteers including PK modelling results, are recommended for patients on haemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). Whenever possible, Daptomycin should be administered following the completion of dialysis on dialysis days (see section 5.2).</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary when administering Daptomycin to patients with mild or moderate hepatic impairment (Child-Pugh Class B) (see section 5.2). No data are available in patients with severe hepatic impairment (Child-Pugh Class C). Therefore caution should be exercised if Daptomycin is given to such patients.</p><p><em>Elderly patients</em></p><p>The recommended doses should be used in elderly patients except those with severe renal impairment (see above and section 4.4).</p><p><em>Paediatric patients (2 to 17 years of age) with complicated skin and soft-tissue infections</em></p><p>The recommended dosage regimens based on age for paediatric patients with cSSTI are shown below.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Age group</p></td><td style="vertical-align:top"><p>Dosage</p></td><td style="vertical-align:top"><p>Duration of therapy</p></td></tr><tr><td style="vertical-align:top"><p>12 to 17 years</p></td><td style="vertical-align:top"><p>5 mg/kg once every 24 hours</p></td><td rowspan="3" style="vertical-align:top"><p>Up to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>7 to 11 years</p></td><td style="vertical-align:top"><p>7 mg/kg once every 24 hours</p></td></tr><tr><td style="vertical-align:top"><p>2 to 6 years</p></td><td style="vertical-align:top"><p>9 mg/kg once every 24 hours</p></td></tr></tbody></table><p>Daptomycin is administered intravenously in 0.9 % sodium chloride (see section 6.6). Daptomycin should not be used more frequently than once a day.</p><p>Creatine phosphokinase (CPK) levels must be measured at baseline and at regular intervals (at least weekly) during treatment (see section 4.4).</p><p>Paediatric patients below the age of one year should not be given Daptomycin due to the risk of potential effects on muscular, neuromuscular and/or nervous systems (either peripheral and/or central) that were observed in neonatal dogs (see section 5.3).</p><p>The safety and efficacy of Daptomycin in children and adolescents aged below 18 years with right-sided infective endocarditis (RIE) due to&nbsp;<em>Staphylococcus aureus</em>&nbsp;or with&nbsp;<em>Staphylococcus aureus</em>&nbsp;bacteraemia (SAB) when associated with RIE or with cSSTI have not been established. Currently available data are described in section 5.2 but no recommendation on a posology can be made.</p><p><u>Method of administration</u></p><p>In adults, Daptomycin is given by intravenous infusion and administered over a 30-minute period or by intravenous injection and administered over a 2-minute period.</p><p>In paediatric patients aged 7 to 17 years, Daptomycin is given by intravenous infusion over a 30-minute period (see section 6.6). In paediatric patients aged 2 to 6 years, Daptomycin is given by intravenous infusion over a 60-minute period (see section 6.6).</p><p>For instructions on reconstitution/dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>If a focus of infection other than cSSTI or RIE is identified after initiation of Daptomycin therapy consideration should be given to instituting alternative antibacterial therapy that has been demonstrated to be efficacious in the treatment of the specific type of infection(s) present.</p><p><u>Anaphylaxis/hypersensitivity reactions</u></p><p>Anaphylaxis/hypersensitivity reactions have been reported with Daptomycin. If an allergic reaction to Daptomycin occurs, discontinue use and institute appropriate therapy.</p><p><u>Pneumonia</u></p><p>It has been demonstrated in clinical studies that Daptomycin is not effective in the treatment of pneumonia. Daptomycin is therefore not indicated for the treatment of pneumonia.</p><p><u>RIE due to&nbsp;<em>Staphylococcus aureus</em></u></p><p>Clinical data on the use of Daptomycin to treat RIE due to&nbsp;<em>Staphylococcus aureus&nbsp;</em>are limited to 19 patients (see &ldquo;Information from clinical trials&rdquo; in section 5.1).</p><p>The efficacy of Daptomycin in patients with prosthetic valve infections or with left-sided infective endocarditis due to <em>Staphylococcus aureus&nbsp;</em>has not been demonstrated.</p><p><u>Deep -seated infections</u></p><p>Patients with deep-seated infections should receive any required surgical interventions (e.g. debridement, removal of prosthetic devices, valve replacement surgery) without delay.</p><p><u>Enterococcal infections</u></p><p>There is insufficient evidence to be able to draw any conclusions regarding the possible clinical efficacy of Daptomycin against infections due to enterococci, including&nbsp;<em>Enterococcus faecalis&nbsp;</em>and&nbsp;<em>Enterococcus faecium</em>. In addition, dose regimens of daptomycin that might be appropriate for the treatment of enterococcal infections, with or without bacteraemia, have not been identified. Failures with daptomycin in the treatment of enterococcal infections that were mostly accompanied by bacteraemia have been reported. In some instances treatment failure has been associated with the selection of organisms with reduced susceptibility or frank resistance to daptomycin (see section 5.1).</p><p><u>Non-susceptible micro-organisms</u></p><p>The use of antibacterials may promote the overgrowth of non-susceptible micro-organisms. If superinfection occurs during therapy, appropriate measures should be taken.</p><p><em><u>Clostridium difficile</u></em><u>-associated diarrhoea</u></p><p><em>Clostridium difficile</em>-associated diarrhoea (CDAD) has been reported with Daptomycin (see section 4.8). If CDAD is suspected or confirmed, Daptomycin may need to be discontinued and appropriate treatment instituted as clinically indicated.</p><p><u>Drug/laboratory test interactions</u></p><p>False prolongation of prothrombin time (PT) and elevation of international normalised ratio (INR) have been observed when certain recombinant thromboplastin reagents are utilised for the assay (see also section 4.5).</p><p><u>Creatine phosphokinase and myopathy</u></p><p>Increases in plasma creatine phosphokinase (CPK; MM isoenzyme) levels associated with muscular pains and/or weakness and cases of myositis, myoglobinaemia and rhabdomyolysis have been reported during therapy with Daptomycin (see also sections 4.5, 4.8 and 5.3). In clinical studies, marked increases in plasma CPK to &gt; 5x Upper Limit of Normal (ULN) without muscle symptoms occurred more commonly in daptomycin-treated patients (1.9%) than in those that received comparators (0.5%). Therefore, it is recommended that:</p><p>&bull; Plasma CPK should be measured at baseline and at regular intervals (at least once weekly) during therapy in all patients.</p><p>&bull; CPK should be measured more frequently (e.g. every 2-3 days at least during the first two weeks of treatment) in patients who are at higher risk of developing myopathy. For example, patients with any degree of renal impairment (creatinine clearance &lt; 80 ml/min; see also section 4.2), including those on haemodialysis or CAPD, and patients taking other medicinal products known to be associated with myopathy (e.g. HMG-CoA reductase inhibitors, fibrates and ciclosporin).</p><p>&bull; It cannot be ruled out that those patients with CPK greater than 5 times upper limit of normal at baseline may be at increased risk of further increases during daptomycin therapy. This should be taken into account when initiating daptomycin therapy and, if daptomycin is given, these patients should be monitored more frequently than once weekly.</p><p>&bull; Daptomycin should not be administered to patients who are taking other medicinal products associated with myopathy unless it is considered that the benefit to the patient outweighs the risk.</p><p>&bull; Patients should be reviewed regularly while on therapy for any signs or symptoms that might represent myopathy.</p><p>&bull; Any patient that develops unexplained muscle pain, tenderness, weakness or cramps should have CPK levels monitored every 2 days. Daptomycin should be discontinued in the presence of unexplained muscle symptoms if the CPK level reaches greater than 5 times upper limit of normal.</p><p><u>Peripheral neuropathy</u></p><p>Patients who develop signs or symptoms that might represent a peripheral neuropathy during therapy with Daptomycin should be investigated and consideration should be given to discontinuation of Daptomycin (see sections 4.8 and 5.3).</p><p><u>Paediatric population</u></p><p>Paediatric patients below the age of one year should not be given Daptomycin due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) that were observed in neonatal dogs (see section 5.3).</p><p><u>Eosinophilic pneumonia</u></p><p>Eosinophilic pneumonia has been reported in patients receiving Daptomycin (see section 4.8). In most reported cases associated with daptomycin, patients developed fever, dyspnoea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates or organising pneumonia. The majority of cases occurred after more than 2 weeks of treatment with daptomycin and improved when daptomycin was discontinued and steroid therapy was initiated. Recurrence of eosinophilic pneumonia upon re-exposure has been reported. Patients who develop these signs and symptoms while receiving Daptomycin should undergo prompt medical evaluation, including, if appropriate, bronchoalveolar lavage, to exclude other causes (e.g. bacterial infection, fungal infection, parasites, other medicinal products). Daptomycin should be discontinued immediately and treatment with systemic steroids should be initiated when appropriate.</p><p><u>Renal impairment</u></p><p>Renal impairment has been reported during treatment with daptomycin. Severe renal impairment may in itself also pre- dispose to elevations in daptomycin levels which may increase the risk of development of myopathy (see above).</p><p>An adjustment of Daptomycin dose interval is needed for patients whose creatinine clearance is &lt; 30 ml/min (see sections 4.2 and 5.2). The safety and efficacy of the dose interval adjustment have not been evaluated in controlled clinical trials and the recommendation is mainly based on pharmacokinetic modelling data. Daptomycin should only be used in such patients when it is considered that the expected clinical benefit outweighs the potential risk.</p><p>Caution is advised when administering Daptomycin to patients who already have some degree of renal impairment (creatinine clearance &lt; 80 ml/min) before commencing therapy with Daptomycin. Regular monitoring of renal function is advised (see also section 5.2).</p><p>In addition, regular monitoring of renal function is advised during concomitant administration of potentially nephrotoxic agents, regardless of the patient&#39;s pre-existing renal function (see also section 4.5).</p><p><u>Obesity</u></p><p>In obese subjects with Body Mass Index (BMI) &gt; 40 kg/m<sup>2</sup>&nbsp;but with creatinine clearance &gt; 70 ml/min, the AUC<sub>0 -&infin;</sub>daptomycin was significantly increased (mean 42% higher) compared with non-obese matched controls. There is limited information on the safety and efficacy of daptomycin in the very obese and so caution is recommended. However, there is currently no evidence that a dose reduction is required (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin undergoes little to no Cytochrome P450 (CYP450) -mediated metabolism. It is unlikely that daptomycin will inhibit or induce the metabolism of medicinal products metabolised by the P450 system.</p><p>Interaction studies for daptomycin were performed with aztreonam, tobramycin, warfarin and probenecid. Daptomycin had no effect on the pharmacokinetics of warfarin or probenecid, nor did these medicinal products alter the pharmacokinetics of daptomycin. The pharmacokinetics of daptomycin were not significantly altered by aztreonam.</p><p>Although small changes in the pharmacokinetics of daptomycin and tobramycin were observed during coadministration by intravenous infusion over a 30-minute period using a Daptomycin dose of 2 mg/kg, the changes were not statistically significant. The interaction between daptomycin and tobramycin with an approved dose of Daptomycin is unknown. Caution is warranted when Daptomycin is co-administered with tobramycin.</p><p>Experience with the concomitant administration of Daptomycin and warfarin is limited. Studies of Daptomycin with anticoagulants other than warfarin have not been conducted. Anticoagulant activity in patients receiving Daptomycin and warfarin should be monitored for the first several days after therapy with Daptomycin is initiated.</p><p>There is limited experience regarding concomitant administration of daptomycin with other medicinal products that may trigger myopathy (e.g. HMG-CoA reductase inhibitors). However, some cases of marked rises in CPK levels and cases of rhabdomyolysis occurred in patients taking one of these medicinal products at the same time as Daptomycin. It is recommended that other medicinal products associated with myopathy should if possible be temporarily discontinued during treatment with Daptomycin unless the benefits of concomitant administration outweigh the risk. If co-administration cannot be avoided, CPK levels should be measured more frequently than once weekly and patients should be closely monitored for any signs or symptoms that might represent myopathy. See sections 4.4, 4.8 and 5.3.</p><p>Daptomycin is primarily cleared by renal filtration and so plasma levels may be increased during coadministration with medicinal products that reduce renal filtration (e.g. NSAIDs and COX-2 inhibitors). In addition, there is a potential for a pharmacodynamic interaction to occur during coadministration due to additive renal effects. Therefore, caution is advised when daptomycin is coadministered with any other medicinal product known to reduce renal filtration.</p><p>During post&ndash;marketing surveillance, cases of interference between daptomycin and particular reagents used in some assays of prothrombin time/international normalised ratio (PT/INR) have been reported. This interference led to a false prolongation of PT and elevation of INR. If unexplained abnormalities of PT/INR are observed in patients taking daptomycin, consideration should be given to a possible in vitro interaction with the laboratory test. The possibility of erroneous results may be minimised by drawing samples for PT or INR testing near the time of trough plasma concentrations of daptomycin (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>No clinical data on pregnancies are available for daptomycin. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).</p><p>Daptomycin should not be used during pregnancy unless clearly necessary i.e., only if the expected benefit outweighs the possible risk.</p><p><u>Breast-feeding</u></p><p>In a single human case study, Daptomycin was intravenously administered daily for 28 days to a nursing mother at a dose of 500 mg/day, and samples of the patient&#39;s breast milk were collected over a 24-hour period on day 27. The highest measured concentration of daptomycin in the breast milk was 0.045 mcg/ml, which is a low concentration. Therefore, until more experience is gained, breast-feeding should be discontinued when Daptomycin is administered to nursing women.</p><p><u>Fertility</u></p><p>No clinical data on fertility are available for daptomycin. Animal studies do not indicate direct or indirect harmful effects with respect to fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>On the basis of reported adverse drug reactions, Daptomycin is presumed to be unlikely to produce an effect on the ability to drive or use machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>In clinical studies, 2,011 subjects received Daptomycin. Within these trials, 1,221 subjects received a daily dose of 4 mg/kg, of whom 1,108 were patients and 113 were healthy volunteers; 460 subjects received a daily dose of 6 mg/kg, of whom 304 were patients and 156 were healthy volunteers. Adverse reactions (i.e. considered by the investigator to be possibly, probably, or definitely related to the medicinal product) were reported at similar frequencies for Daptomycin and comparator regimens.</p><p>The most frequently reported adverse reactions (frequency common (&ge; 1/100 to &lt; 1/10)) are:</p><p>Fungal infections, urinary tract infection, candida infection, anaemia, anxiety, insomnia, dizziness, headache, hypertension, hypotension, gastrointestinal and abdominal pain, nausea, vomiting, constipation, diarrhoea, flatulence, bloating and distension, liver function tests abnormal (increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP)), rash, pruritus, limb pain, serum creatine phosphokinase (CPK) increased, infusion site reactions, pyrexia, asthenia.</p><p>Less frequently reported, but more serious, adverse reactions include hypersensitivity reactions, eosinophilic pneumonia (occasionally presenting as organizing pneumonia), drug rash with eosinophilia and systemic symptoms (DRESS), angioedema and rhabdomyolysis.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions were reported during therapy and during follow-up with frequencies corresponding to very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data):</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><strong>Table 1 Adverse reactions from clinical studies and post-marketing reports</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Fungal infections, urinary tract infection, candida infection</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Fungaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known*:</em></p></td><td style="vertical-align:top"><p><em>Clostridium difficile</em>-associated diarrhoea**</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Thrombocythaemia, eosinophilia, international normalised ratio (INR) increased, leukocytosis</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>Prothrombin time (PT) prolonged</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known*</em></p></td><td style="vertical-align:top"><p>Thrombocytopaenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><em>Not known*:</em></p></td><td style="vertical-align:top"><p>Hypersensitivity**, manifested by isolated spontaneous reports including, but not limited to angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), pulmonary eosinophilia, vesicobullous rash with mucous membrane involvement and sensation of oropharyngeal swelling, anaphylaxis**, infusion reactions including the following symptoms: tachycardia, wheezing, pyrexia, rigors, systemic flushing, vertigo, syncope and metallic taste</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Decreased appetite, hyperglycaemia, electrolyte imbalance</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Anxiety, insomnia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Dizziness, headache</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Paraesthesia, taste disorder, tremor, eye irritation</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known*:</em></p></td><td style="vertical-align:top"><p>Peripheral neuropathy**</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Supraventricular tachycardia, extrasystole</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Hypertension, hypotension</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Flushes</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p><em>Not known*:</em></p></td><td style="vertical-align:top"><p>Eosinophilic pneumonia1 **, cough</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Gastrointestinal and abdominal pain, nausea, vomiting, constipation, diarrhoea, flatulence, bloating and distension</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Dyspepsia, glossitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Liver function tests abnormal2 (increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP))</p></td></tr><tr><td style="vertical-align:top"><p><em>Rare:</em></p></td><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known*</em></p></td><td style="vertical-align:top"><p>Acute generalised exanthematous pustulosis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Limb pain, serum creatine phosphokinase (CPK)2 increased</p></td></tr><tr><td rowspan="2" style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Myositis, increased myoglobin, muscular weakness, muscle pain, arthralgia, serum lactate dehydrogenase (LDH) increased, muscle cramps</p></td></tr><tr><td style="vertical-align:top"><p><em>Not known*:</em></p></td><td style="vertical-align:top"><p>Rhabdomyolysis<sup>3</sup>&nbsp;**</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Renal impairment, including renal failure and renal insufficiency, serum creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Vaginitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><em>Common:</em></p></td><td style="vertical-align:top"><p>Infusion site reactions, pyrexia, asthenia</p></td></tr><tr><td style="vertical-align:top"><p><em>Uncommon:</em></p></td><td style="vertical-align:top"><p>Fatigue, pain</p></td></tr></tbody></table><p>* Based on post-marketing reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known.</p><p>** See section 4.4.</p><p><sup>1</sup>&nbsp;While the exact incidence of eosinophilic pneumonia associated with daptomycin is unknown, to date the reporting rate of spontaneous reports is very low (&lt; 1/10,000).</p><p><sup>2</sup>&nbsp;In some cases of myopathy involving raised CPK and muscle symptoms, the patients also presented with elevated transaminases. These transaminase increases were likely to be related to the skeletal muscle effects. The majority of transaminase elevations were of Grade 1-3 toxicity and resolved upon discontinuation of treatment.</p><p><sup>3&nbsp;</sup>When clinical information on the patients was available to make a judgement, approximately 50% of the cases occurred in patients with pre-existing renal impairment, or in those receiving concomitant medicinal products known to cause rhabdomyolysis.</p><p>The safety data for the administration of daptomycin via 2-minute intravenous injection are derived from two pharmacokinetic studies in healthy volunteers. Based on these study results, both methods of daptomycin administration, the 2-minute intravenous injection and the 30-minute intravenous infusion, had a similar safety and tolerability profile. There was no relevant difference in local tolerability or in the nature and frequency of adverse reactions.</p><p>&nbsp;</p><p><strong>To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:.65pt;margin-top:6.05pt;width:375.05pt;height:122.65pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEABKOYUjgFAABpIAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWtty2zYQfe9M/wGDp3ZaWRJ1szWh
U0e2MplxHI3lTJ8hEJIwAUEWgG55zE/1s/oLPQB1odi07iRp2jSSxhRILJe7Z3ex4K6fPF2niiyF
sTLTMW2eNSgRmmeJ1LOYvn4Y1s4psY7phKlMi5huhKVPL7/95gnrzwzL55ITcNC2z2I6dy7v1+uW
z0XK7FmWC425aWZS5nBqZvXEsBU4p6oeNRrdesqkppcHVtfMMbIw8gNYqYy/EcmA6SWzYKl4v3xl
K6PiH8+Z9fXyucnH+ch4yfndcmSITGIK5DRLARGtbye2ZDitV+6aHRispyb19Nl0StYxvYiibqdD
ySam7W7UOz9vFOzE2hGO+Xav22q2QMBB0ex0ep66eOD81V+z4PObR5hAzEIcDEoi2twLqJd/1Lm9
0/nBy/csW5Nor72nJm6NixA0WNnmt7CSJTobzJmeiStjstVcsMR6igIm4Fk8JkC2e6L1vCarl1kC
fNnCZYHfJ4JurzXr58a65yJLiR/E1AjuwpPY8ta6QsAdiYfEZkomQ6lUODGzyUAZsmQqpsPw2ep0
RKY0WcHMnahTYPKnLBrh8z4WqXTCECXTmJ7viVjfI3mjk+AMjklVjKGd0sEDPYheULceB4N62yQb
f2WCXwBsMugMN8Zy4F7hMFUZROVK5pTMM/O2es3TIaAwQ8kKi0FM7S8LZgQl6oWGTS+a7TbYuXDS
7vQinJjyzKQ8wzQHq5g6SorhwOEMtyxyI2dzPKnwIp1dwQGmcmuPQnavhbJu7DZKBACCht5rUmZu
AxsM7sOAqRmWOgVZHCxVMFV6nPNgxZyPuCuM2Gz0AO/WAmWKZ2K6o3W2oN2R2ZwfZq+mrkoHg+1M
mvMwDwNtDROsYyCzQnTEVOja6zFW37cQsonbPCsxncInC2eExsxJTdwmF1PGERkPMhX2Tqzus5Tp
0fjlg38UbmJVGgIiEqgoyZnOLG5uRPh2G61Gp9HGX4QRwjuXjs+HLJXKrzdIBnzOjBXBUQJzbqvM
qwJAQSjlBXGXd5A400yREdikjGdLOZNQlwsYPSHXZjEjYzYVbkMGQjsjyHd3o8H3pO+XUIDpeQWV
dDJiht1/BFgDpuTEyCMAhkFxD0Qb6uNYAaCFC1UAPh+6V0YyuG3JYM9gsDbk3H0flxcAij12Ac8i
Ujyoh3BptaMLeJwPniJm1BKhggtSJzBLTGtbCn9bOTIOsdPsfPLYQRBUgwdr12KYaVfywfEmnWRl
mDowahMQ+XDu4rfT6FXMeuTX2ww2WSBJmWDtmP727tdt1H49oTpk6z754aLbrTWbNaBW63W70SkM
Y3oKw1MYfr6MiTSlCHIgYa4Uja3zKKoG40dvH77ajLjfnpAfjxY4JMv3ZcewlS1lx387CXoxiw3W
yQWQ3z9oU7R3gZsjD9huNzH7P96U49U9ajV7tajV6eLQblQgOGwYPxiEr3ZpOWB32my/5yXytNn2
ycNdjofXVySkev/aK0yfNC/wOQXiabt9euv9nAWqmxqaEqpPKpH3yMaKLFD71DPqg/mo2mvLRWFf
qx0Od+W/cuH3SyzroeCspH4zUJK/2fZXUK99vAeERofk4jrjixRLXdEIMsKXMjNt5zK3KMz2fUPF
vEh2XYH97kzn/CxBkfAnO03Y2SxbnllWMdUh4552K/vC4N8pZZ5Kg/+h0uAnrNB/cQXqfbT/LCYW
va4+Wa1WZ6eIP2q1/GNVSCwDh87gwopxfo+WE3o9YcK3DjHwLeF6pckeJrb/FOA7+eXzy98BAAD/
/wMAUEsDBBQABgAIAAAAIQDhUTcfzwYAAOYbAAAaAAAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54
bWzsWc1v3EQUvyPxP4x8b7PfzUbdVNnNbgNt2ijZFvU4a8/a04w91sxs0r2h9oiEhCiIA5W4cUBA
pVbiUv6aQBEUqf8Cb2ZsryfrkLSNoILmkLWff/O+35uvy1fuxQwdECEpT3pe/WLNQyTxeUCTsOfd
Go8urHpIKpwEmPGE9Lw5kd6V9fffu4zXfEbTCcciGEckJggYJXIN97xIqXRtZUX6QMbyIk9JAt+m
XMRYwasIVwKBD0FAzFYatVpnJcY08daBo9KMhgz+JUpqgs/EnmZDUIJjkH5zOqU+Mdhgv64Rci4H
TKADzHoe8Az44ZjcUx5iWCr40PNq5s9bWb+8gteyQUydMLY0bmT+snHZgGC/YWSKcFIIrY9a3Uub
BX8DYGoZNxwOB8N6wc8AsO+DpVaXMs/WaLXez3mWQPZxmfeg1q61XHyJf3NJ526/3293M10sUwOy
j60l/Gqt09poOHgDsvj2Er7V3xgMOg7egCy+s4QfXep2Wi7egCJGk/0ltA7oaJRxLyBTzrYq4asA
X61l8AUKsqHILi1iyhN1Uq7F+C4XIwBoIMOKJkjNUzLFPuTkAMcTQbEWgNcILn2xJF8ukbQsJH1B
U9XzPkxx4pUgL599//LZE3R0/+nR/Z+OHjw4uv+jZeSM2sJJWB714tvP/nz0MfrjyTcvHn5RjZdl
/K8/fPLLz59XA6F8FuY9//Lxb08fP//q09+/e1gB3xB4UoaPaUwkukEO0S6PwTDjFVdzMhGvNmIc
YVoesZGEEidYS6ngP1SRg74xxyyLjqNHn7gevC2gfVQBr87uOgrvRWKmaIXka1HsALc5Z30uKr1w
TcsquXk8S8Jq4WJWxu1ifFAle4ATJ77DWQp9M09Lx/BBRBw1dxhOFA5JQhTS3/g+IRXW3aHU8es2
9QWXfKrQHYr6mFa6ZEwnTjYtBm3RGOIyr7IZ4u34Zvs26nNWZfUmOXCRUBWYVSg/Jsxx41U8Uziu
YjnGMSs7/DpWUZWSe3Phl3FDqSDSIWEcDQMiZdWYmwLsLQX9GoaOVRn2bTaPXaRQdL+K53XMeRm5
yfcHEY7TKuweTaIy9gO5DymK0Q5XVfBt7laIfoc44OTEcN+mxAn36d3gFg0dlRYJor/MhI4ltGqn
A8c0+bt2zCj0Y5sD59eOoQE+//pRRWa9rY14A+akqkrYOtZ+T8Idb7oDLgL69vfcTTxLdgik+fLE
867lvmu53n++5Z5Uz2dttIveCm1XrxvsotgskeMTV8hTytiemjNyXZpFsoR5IhgBUY8zO0FS7JjS
CB6zvu7gQoHNGCS4+oiqaC/CKSyw655mEsqMdShRyiVs7Ay5krfGwyJd2W1hW28YbD+QWG3zwJKb
mpzvCwo2ZrYJzeYzF9TUDM4qrHkpYwpmv46wulbqzNLqRjXT6hxphckQw2XTgFh4ExYgCJYt4OUO
7MW1aNiYYEYC7Xc79+ZhMVE4zxDJCAcki5G2ezlGdROkPFfMSQDkTkWM9CbvFK+VpHU12zeQdpYg
lcW1ThCXR+9NopRn8CJKum6PlSNLysXJEnTY87rtRttDPk573hT2tPAYpxB1qdd8mIVwGuQrYdP+
1GI2Vb6IZjc3zC2COhxTWL8vGez0gVRItYllZFPDfMpSgCVaktW/0Qa3npcBNtNfQ4vmKiTDv6YF
+NENLZlOia/KwS5RtO/sa9ZK+UwRsRcFh2jCZmIXQ/h1qoI9AZVwNGE6gn6BczTtbfPJbc5Z0ZVP
rwzO0jFLI5y1W12ieSVbuKnjQgfzVlIPbKvU3Rj36qaYkj8nU8pp/D8zRc8ncFLQDHQEfDiUFRjp
eu15XKiIQxdKI+qPBCwcTO+AbIGzWPgMSQUnyOZXkAP9a2vO8jBlDRs+tUtDJCjMRyoShOxAWzLZ
dwqzejZ3WZYsY2QyqqSuTK3aE3JA2Fj3wI6e2z0UQaqbbpK1AYM7nn/ue1ZBk1Avcsr15vSQYu61
NfBPr3xsMYNRbh82C5rc/4WKFbOqHW+G53Nv2RD9YbHMauVVAcJKU0E3K/vXVOEVp1rbsZYsbrRz
5SCKyxYDsVgQpXDeg/Q/mP+o8Jm9bdAT6pjvQm9FcNGgmUHaQFZfsAsPpBukJU5g4WSJNpk0K+va
bOmkvZZP1ue80i3kHnO21uws8X5FZxeLM1ecU4vn6ezMw46vLe1EV0Nkj5cokKb5RsYEpurWaRun
aBLWex7c/ECg78ET3B15QGtoWkPT4AkuhGCxZG9xel72kFPgu6UUmGZOaeaYVk5p5ZR2ToHFWXZf
klM60Kn0FQdcsekfD+W3GbCCy24/8qbqXM2t/wUAAP//AwBQSwMEFAAGAAgAAAAhAFOr2/ztAAAA
zQEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHOskcFqAyEQ
QO+F/oPMvbqbQykhbnJoCzn0UtIPGHTWlayjqAnJ31caShsI9NLLgDP65jmzWp/CLI6Ui4+soZcd
CGITrWen4WP3+vAEolRki3Nk0nCmAuvh/m71TjPW9qhMPhXRKFw0TLWmpVLFTBSwyJiIW2WMOWBt
x+xUQrNHR2rRdY8q/2bAcMUUW6shb+0CxO6cWue/2XEcvaHnaA6BuN5ooWrzogbE7KhqkPKSucRe
NldQtzX6/9SY2ofy7Hn/oxLQzzUuORlp88FtymhRuniUBb8vvUXbxvByqpQZv0TV1RKGTwAAAP//
AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRf
VHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABf
cmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAEo5hSOAUAAGkgAAAfAAAAAAAAAAAAAAAAACACAABj
bGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAOFRNx/PBgAA5hsA
ABoAAAAAAAAAAAAAAAAAlQcAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgA
AAAhAFOr2/ztAAAAzQEAACoAAAAAAAAAAAAAAAAAnA4AAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVs
cy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAADRDwAAAAA=
">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=right dir=RTL style='text-align:left;mso-layout-grid-align:
    none;text-autospace:none'><span dir=LTR style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>National Pharmacovigilance and Drug
    Safety Centre (NPC) :<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Fax:
    +966-11-205-7662<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Call NPC
    at +966-11-2038222</span> ,<span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;line-height:115%;mso-layout-grid-align:none;text-autospace:none'>E<span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>xt
    2317-2356-2340<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>SFDA Call
    Center: 19999<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    class=MsoHyperlink><span style='font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol;text-decoration:none;text-underline:
    none'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span></span><![endif]><span dir=LTR></span><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>E-mail:
    </span><a href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>npc.drug@sfda.gov.sa</span></a><span
    class=MsoHyperlink><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></span></p>
    <p class=MsoListParagraphCxSpLast style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-.25in;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "Times New Roman",serif'>Website: www.sfda.gov.sa</span><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="506" height="170" alt="Text Box: National Pharmacovigilance and Drug Safety Centre (NPC) :
•	Fax: +966-11-205-7662
•	Call NPC at +966-11-2038222 ,
Ext 2317-2356-2340
•	SFDA Call Center: 19999
•	E-mail: npc.drug@sfda.gov.sa
•	Website: www.sfda.gov.sa
" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, supportive care is advised. Daptomycin is slowly cleared from the body by haemodialysis (approximately 15% of the administered dose is removed over 4 hours) or by peritoneal dialysis (approximately 11% of the administered dose is removed over 48 hours).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 Pharmacodynamic properties</strong></p><p>Pharmacotherapeutic group: Antibacterials for systemic use, Other antibacterials, ATC code: J01XX09</p><p><u>Mechanism of action</u></p><p>Daptomycin is a cyclic lipopeptide natural product that is active against Gram positive bacteria only.</p><p>The mechanism of action involves binding (in the presence of calcium ions) to bacterial membranes of both growing and stationary phase cells causing depolarisation and leading to a rapid inhibition of protein, DNA, and RNA synthesis. This results in bacterial cell death with negligible cell lysis.</p><p><u>PK/PD relationship</u></p><p>Daptomycin exhibits rapid, concentration dependent bactericidal activity against Gram positive organisms&nbsp;<em>in vitro&nbsp;</em>and in&nbsp;<em>in vivo&nbsp;</em>animal models. In animal models AUC/MIC and C<sub>max</sub>/MIC correlate with efficacy and predicted bacterial kill&nbsp;<em>in vivo</em>&nbsp;at single doses equivalent to human doses of 4 mg/kg and 6 mg/kg once daily.</p><p><u>Mechanisms of resistance</u></p><p>Strains with decreased susceptibility to daptomycin have been reported especially during the treatment of patients with difficult-to-treat infections and/or following administration for prolonged periods. In particular, there have been reports of treatment failures in patients infected with&nbsp;<em>Staphylococcus aureus, Enterococcus faecalis or Enterococcus faecium,&nbsp;</em>including bacteraemic patients, that have been associated with the selection of organisms with reduced susceptibility or frank resistance to daptomycin during therapy.</p><p>The mechanism(s) of daptomycin resistance is (are) not fully understood.</p><p><u>Breakpoints</u></p><p>Minimum inhibitory concentration (MIC) breakpoint established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for Staphylococci and Streptococci (except&nbsp;<em>S. pneumoniae</em>) are Susceptible &le; 1 mg/l and Resistant &gt; 1 mg/l.</p><p><em>Susceptibility</em></p><p>The prevalence of resistance may vary geographically and over time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly Susceptible Species</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus&nbsp;</em>*</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus haemolyticus</em></p></td></tr><tr><td style="vertical-align:top"><p>Coagulase negative staphylococci</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus agalactiae</em>*</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus dysgalactiae&nbsp;</em>subsp&nbsp;<em>equisimilis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pyogenes</em>*</p></td></tr><tr><td style="vertical-align:top"><p>Group G streptococci</p></td></tr><tr><td style="vertical-align:top"><p><em>Clostridium perfringens</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Peptostreptococcus spp</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p>Gram negative organisms</p></td></tr></tbody></table><p><strong>*&nbsp;</strong>denotes species against which it is considered that activity has been satisfactorily demonstrated in clinical studies.</p><p><u>Clinical efficacy and safety</u></p><p>In two clinical trials in complicated skin and soft tissues infections, 36% of patients treated with Daptomycin met the criteria for systemic inflammatory response syndrome (SIRS). The most common type of infection treated was wound infection (38% of patients), while 21% had major abscesses. These limitations of the patients population treated should be taken into account when deciding to use Daptomycin.</p><p>In a randomised controlled open-label study in 235 patients with&nbsp;<em>Staphylococcus aureus</em>&nbsp;bacteraemia (i.e, at least one positive blood culture of&nbsp;<em>Staphylococcus aureus</em>&nbsp;prior to receiving the first dose) 19 of 120 patients treated with Daptomycin met the criteria for RIE. Of these 19 patients 11 were infected with methicillin -susceptible and 8 with methicillin -resistant&nbsp;<em>Staphylococcus aureus</em>. The success rates in RIE patients are shown in the table below.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Population</strong></p></td><td style="vertical-align:top"><p><strong>Daptomycin</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p></td><td style="vertical-align:top"><p><strong>Differences in Success</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Rates (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ITT (intention to treat) Population</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>RIE</p></td><td style="vertical-align:top"><p>8/19 (42.1%)</p></td><td style="vertical-align:top"><p>7/16 (43.8%)</p></td><td style="vertical-align:top"><p>-1.6% (-34.6, 31.3)</p></td></tr><tr><td style="vertical-align:top"><p>PP (per protocol) Population</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>RIE</p></td><td style="vertical-align:top"><p>6/12 (50.0%)</p></td><td style="vertical-align:top"><p>4/8 (50.0%)</p></td><td style="vertical-align:top"><p>0.0% (-44.7, 44.7)</p></td></tr></tbody></table><p>Failure of treatment due to persisting or relapsing&nbsp;<em>Staphylococcus aureus</em>&nbsp;infections was observed in 19/120 (15.8%) patients treated with Daptomycin, 9/53 (16.7%) patients treated with vancomycin and 2/62 (3.2%) patients treated with an anti-staphylococcal semi-synthetic penicillin. Among these failures six patients treated with Daptomycin and one patient treated with vancomycin were infected with&nbsp;<em>Staphylococcus aureus</em>&nbsp;that developed increasing MICs of daptomycin on or following therapy (see &ldquo;Mechanisms of resistance&rdquo; above). Most patients who failed due to persisting or relapsing&nbsp;<em>Staphylococcus aureus</em>&nbsp;infection had deep-seated infection and did not receive necessary surgical intervention.</p><p>The safety and efficacy of daptomycin was evaluated in paediatric patients aged 1 to 17 years (Study DAP-PEDS-07-03) with cSSTI caused by Gram positive pathogens. Patients were enrolled in a stepwise approach into well-defined age groups and given age-dependent doses once daily for up to 14 days, as follows:</p><p>&bull; Age group 1 (n=113): 12 to 17 years treated with daptomycin dosed at 5 mg/kg or standard-of-care (SOC);</p><p>&bull; Age group 2 (n=113): 7 to 11 years treated with daptomycin dosed at 7 mg/kg or SOC;</p><p>&bull; Age group 3 (n=125): 2 to 6 years treated with daptomycin dosed at 9 mg/kg or SOC;</p><p>&bull; Age group 4 (n=45): 1 to &lt; 2 years treated with daptomycin dosed at 10 mg/kg or SOC.</p><p>The primary objective of Study DAP-PEDS-07-03 was to assess the safety of treatment. Secondary objectives included an assessment of efficacy of age-dependent doses of intravenous daptomycin in comparison with standard-of-care therapy. The key efficacy endpoint was the sponsor-defined clinical outcome at test-of-cure (TOC), which was defined by a blinded medical director.</p><p>A total of 389 subjects were treated in the study, including 256 subjects who received daptomycin and 133 subjects who received standard-of-care. In all populations the clinical success rates were comparable between the daptomycin and SOC treatment arms, supporting the primary efficacy analysis in the ITT population.</p><p>Summary of sponsor-defined clinical outcome at test-of-cure:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p>Clinical Success</p></td></tr><tr><td style="vertical-align:top"><p>DAP</p><p>n/N (%)</p></td><td style="vertical-align:top"><p>SOC</p><p>n/N (%)</p></td><td style="vertical-align:top"><p>% difference</p></td></tr><tr><td style="vertical-align:top"><p>Intent-to-treat</p></td><td style="vertical-align:top"><p>227/257 (88.3%)</p></td><td style="vertical-align:top"><p>114/132 (86.4%)</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Modified intent-to-treat</p></td><td style="vertical-align:top"><p>186/210 (88.6%)</p></td><td style="vertical-align:top"><p>92/105 (87.6%)</p></td><td style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Clinically evaluable</p></td><td style="vertical-align:top"><p>204/207 (98.6%)</p></td><td style="vertical-align:top"><p>99/99 (100%)</p></td><td style="vertical-align:top"><p>-1.5</p></td></tr><tr><td style="vertical-align:top"><p>Microbiologically evaluable (ME)</p></td><td style="vertical-align:top"><p>164/167 (98.2%)</p></td><td style="vertical-align:top"><p>78/78 (100%)</p></td><td style="vertical-align:top"><p>-1.8</p></td></tr></tbody></table><p>The overall therapeutic response rate also was similar for the daptomycin and SOC treatment arms for infections caused by MRSA, MSSA and&nbsp;<em>Streptococcus pyogenes&nbsp;</em>(see table below; ME population); response rates were &gt; 94% for both treatment arms across these common pathogens.</p><p>Summary of overall therapeutic response by type of baseline pathogen (ME population):</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Pathogen</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Success&nbsp;<sup>a</sup>&nbsp;rate n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Daptomycin</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p></td></tr><tr><td style="vertical-align:top"><p>Methicillin -susceptible&nbsp;<em>Staphylococcus aureus</em></p><p>(MSSA)</p></td><td style="vertical-align:top"><p>68/69 (99%)</p></td><td style="vertical-align:top"><p>28/29 (97%)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin -resistant&nbsp;<em>Staphylococcus aureus</em></p><p>(MRSA)</p></td><td style="vertical-align:top"><p>63/66 (96%)</p></td><td style="vertical-align:top"><p>34/34 (100%)</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pyogenes</em></p></td><td style="vertical-align:top"><p>17/18 (94%)</p></td><td style="vertical-align:top"><p>5/5 (100%)</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Subjects achieving clinical success (Clinical Response of &ldquo;Cure&rdquo; or &ldquo;Improved&rdquo;) and microbiological success (pathogen&ndash;level response of &ldquo;Eradicated&rdquo; or &ldquo;Presumed Eradicated&rdquo;) are classified as overall therapeutic success.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin pharmacokinetics are generally linear and time-independent at doses of 4 to 12 mg/kg administered as a single daily dose by 30-minute intravenous infusion for up to 14 days in healthy volunteers. Steady-state concentrations are achieved by the third daily dose.</p><p>Daptomycin administered as a 2-minute intravenous injection also exhibited dose proportional pharmacokinetics in the approved therapeutic dose range of 4 to 6 mg/kg. Comparable exposure (AUC and C<sub>max</sub>) was demonstrated in healthy subjects following administration of daptomycin as a 30-minute intravenous infusion or as a 2-minute intravenous injection.</p><p>Animal studies showed that daptomycin is not absorbed to any significant extent after oral administration.</p><p><u>Distribution</u></p><p>The volume of distribution at steady state of daptomycin in healthy adult subjects was approximately 0.1 l/kg and was independent of dose. Tissue distribution studies in rats showed that daptomycin appears to only minimally penetrate the blood-brain barrier and the placental barrier following single and multiple doses.</p><p>Daptomycin is reversibly bound to human plasma proteins in a concentration independent manner. In healthy volunteers and patients treated with daptomycin, protein binding averaged about 90% including subjects with renal impairment.</p><p><u>Biotransformation</u></p><p>In&nbsp;<em>in vitro&nbsp;</em>studies, daptomycin was not metabolised by human liver microsomes.&nbsp;<em>In vitro&nbsp;</em>studies with human hepatocytes indicate that daptomycin does not inhibit or induce the activities of the following human cytochrome P450 isoforms: 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A4. It is unlikely that daptomycin will inhibit or induce the metabolism of medicinal products metabolised by the P450 system.</p><p>After infusion of 14C-daptomycin in healthy adults, the plasma radioactivity was similar to the concentration determined by microbiological assay. Inactive metabolites were detected in urine, as determined by the difference in total radioactive concentrations and microbiologically active concentrations. In a separate study, no metabolites were observed in plasma, and minor amounts of three oxidative metabolites and one unidentified compound were detected in urine. The site of metabolism has not been identified.</p><p><u>Elimination</u></p><p>Daptomycin is excreted primarily by the kidneys. Concomitant administration of probenecid and daptomycin has no effect on daptomycin pharmacokinetics in humans suggesting minimal to no active tubular secretion of daptomycin.</p><p>Following intravenous administration, plasma clearance of daptomycin is approximately 7 to 9 ml/h/kg and its renal clearance is 4 to 7 ml/h/kg.</p><p>In a mass balance study using radiolabelled material, 78% of the administered dose was recovered from the urine based on total radioactivity, whilst urinary recovery of unchanged daptomycin was approximately 50% of the dose. About 5% of the administered radiolabel was excreted in the faeces.</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>Following administration of a single 4 mg/kg intravenous dose of Daptomycin over a 30-minute period, the mean total clearance of daptomycin was approximately 35% lower and the mean AUC<sub>0 -&infin;</sub>&nbsp;was approximately 58% higher in elderly subjects (&ge; 75 years of age) compared with those in healthy young subjects (18 to 30 years of age). There were no differences in C<sub>max</sub>. The differences noted are most likely due to the normal reduction in renal function observed in the geriatric population.</p><p>No dose adjustment is necessary based on age alone. However, renal function should be assessed and the dose should be reduced if there is evidence of severe renal impairment.</p><p><em>Children and adolescents (&lt; 18 years of age)</em></p><p>The pharmacokinetics of daptomycin after a single 4 mg/kg dose of Daptomycin were evaluated in three groups of paediatric patients with proven or suspected Gram-positive infection (2-6 years, 7-11 years and 12-17 years). The pharmacokinetics of daptomycin following a single 4 mg/kg dose in adolescents aged 12-17 years are generally similar to those of healthy adult subjects with normal renal function with trends towards lower AUC and C<sub>max</sub>&nbsp;in adolescents. In the younger age groups (2-6 years and 7-11 years), total clearance was higher compared with that in adolescents, resulting in a lower level of exposure (AUC and C<sub>max</sub>) and elimination half-life. Efficacy was not assessed in this study.</p><p><em>Obesity</em></p><p>Relative to non-obese subjects daptomycin systemic exposure measured by AUC was about 28% higher in moderately obese subjects (Body Mass Index of 25-40 kg/m2 ) and 42% higher in extremely obese subjects (Body Mass Index of &gt; 40 kg/m2 ). However, no dose adjustment is considered to be necessary based on obesity alone.</p><p><em>Gender</em></p><p>No clinically significant gender-related differences in daptomycin pharmacokinetics have been observed.</p><p><em>Renal impairment</em></p><p>Following administration of a single 4 mg/kg or 6 mg/kg intravenous dose of daptomycin over a 30-minute period to subjects with various degrees of renal impairment, total daptomycin clearance (CL) decreased and systemic exposure (AUC) increased as renal function (creatinine clearance) decreased.</p><p>Based on pharmacokinetic data and modelling, the daptomycin AUC during the first day after administration of a 6 mg/kg dose to patients on HD or CAPD was 2-fold higher than that observed in patients with normal renal function who received the same dose. On the second day after administration of a 6 mg/kg dose to HD and CAPD patients the daptomcyin AUC was approximately 1.3 -fold higher than that observed after a second 6 mg/kg dose in patients with normal renal function. On this basis, it is recommended that patients on HD or CAPD receive daptomycin once every 48 hours at the dose recommended for the type of infection being treated (see section 4.2).</p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of daptomycin is not altered in subjects with moderate hepatic impairment (Child-Pugh B classification of hepatic impairment) compared with healthy volunteers matched for gender, age and weight following a single 4 mg/kg dose. No dosage adjustment is necessary when administering daptomycin in patients with moderate hepatic impairment. The pharmacokinetics of daptomycin in patients with severe hepatic impairment (Child-Pugh C classification) have not been evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In studies of clinically-relevant duration (14-28 days), daptomycin administration was associated with minimal to mild degenerative/regenerative changes in skeletal muscle in the rat and dog. Microscopic changes in skeletal muscle were minimal (approximately 0.05% of myofibres affected) and at the higher doses were accompanied by elevations in CPK. No fibrosis or rhabdomyolysis was observed. Depending on the study duration, all muscle effects, including microscopic changes, were fully reversible within 1-3 months following cessation of dosing. No functional or pathological changes in smooth or cardiac muscle were observed.</p><p>The lowest observable effect level (LOEL) for myopathy in rats and dogs occurred at exposure levels of 0.8 to 2.3 -fold the human therapeutic levels at 6 mg/kg (30-minute intravenous infusion) for patients with normal renal function. As the pharmacokinetics (see section 5.2) is comparable, the safety margins for both methods of administration are very similar.</p><p>A study in dogs demonstrated that skeletal myopathy was reduced upon once daily administration as compared to fractionated dosing at same total daily dose, suggesting that myopathic effects in animals were primarily related to time between doses.</p><p>Effects on peripheral nerves were observed at higher doses than those associated with skeletal muscle effects in adult rats and dogs, and were primarily related to plasma C<sub>max</sub>. Peripheral nerve changes were characterised by minimal to slight axonal degeneration and were frequently accompanied by functional changes. Reversal of both the microscopic and functional effects was complete within 6 months post-dose. Safety margins for peripheral nerve effects in rats and dogs are 8- and 6-fold, respectively, based on comparison of C<sub>max</sub>&nbsp;values at the No Observed Effect Level (NOEL) with the C<sub>max</sub>&nbsp;achieved on dosing with 30-minute intravenous infusion of 6 mg/kg once daily in patients with normal renal function.</p><p>The findings of&nbsp;<em>in vitro&nbsp;</em>and some&nbsp;<em>in vivo&nbsp;</em>studies designed to investigate the mechanism of daptomycin myotoxicity indicate that the plasma membrane of differentiated spontaneously contracting muscle cells is the target of toxicity. The specific cell surface component directly targeted has not been identified. Mitochondrial loss/damage was also observed; however the role and significance of this finding in the overall pathology are unknown. This finding was not associated with an effect on muscle contraction.</p><p>In contrast to adult dogs, juvenile dogs appeared to be more sensitive to peripheral nerve lesions as compared to skeletal myopathy. Juvenile dogs developed peripheral and spinal nerve lesions at doses lower than those associated with skeletal muscle toxicity.</p><p>In neonatal dogs, daptomycin caused marked clinical signs of twitching, muscle rigidity in the limbs, and impaired use of limbs, which resulted in decreases in body weight and overall body condition at doses &ge;50 mg/kg/day and necessitated early discontinuation of treatment in these dose groups. At lower dose levels (25 mg/kg/day), mild and reversible clinical signs of twitching and one incidence of muscle rigidity were observed without any effects on body weight. There was no histopathological correlation in the peripheral and central nervous system tissue, or in the skeletal muscle, at any dose level, and the mechanism and clinical relevance for the adverse clinical signs are therefore unknown.</p><p>Reproductive toxicity testing showed no evidence of effects on fertility, embryofetal, or postnatal development. However, daptomycin can cross the placenta in pregnant rats (see section 5.2). Excretion of daptomycin into milk of lactating animals has not been studied.</p><p>Long-term carcinogenicity studies in rodents were not conducted. Daptomycin was not mutagenic or clastogenic in a battery of&nbsp;<em>in vivo&nbsp;</em>and&nbsp;<em>in vitro&nbsp;</em>genotoxicity tests.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium hydroxide</p><p>Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin is not physically or chemically compatible with glucose-containing solutions. This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
After reconstitution: Chemical and physical in-use stability of the reconstituted solution in the vial has been demonstrated for 12 hours at 25°C and up to 48 hours at 2°C – 8°C. Chemical and physical stability of the diluted solution in infusion bags is established as 12 hours at 25°C or 24 hours at 2°C – 8°C.
For the 30-minute intravenous infusion, the combined storage time (reconstituted solution in vial and diluted solution in infusion bag; see section 6.6) at 25°C must not exceed 12 hours (or 24 at 2°C – 8°C).
For the 2-minute intravenous injection, the storage time of the reconstituted solution in the vial (see section 6.6) at 25°C must not exceed 12 hours (or 48 at 2°C – 8°C).
However, from a microbiological point of view the product should be used immediately. No preservative or bacteriostatic agent is present in this product. If not used immediately, in-use storage times are the responsibility of the user and would not normally be longer than 24 hours at 2°C – 8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>For storage conditions after reconstitution and after reconstitution and dilution of the medicinal product see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear Tubular Glass Vial 15ml Type I with Rubber Stopper 20mm Lyo.</p><p>Pack size: 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin In adults, daptomycin may be administered intravenously as an infusion over 30</p><p>minutes or as an injection over 2 minutes. Daptomycin should not be administered as a 2‐minute</p><p>injection to pediatric patients.</p><p>Pediatric patients 7 to 17 years old should receive daptomycin infused over 30 minutes. In pediatric</p><p>patients under 7 years old receiving a 9‐12 mg/kg dose, daptomycin should be administered over 60</p><p>minutes (see sections 4.2 and 5.2). Preparation of the solution for infusion requires an additional</p><p>dilution step as detailed below.</p><p><u>&nbsp;Daptomycin given as 30 or 60-minute intravenous infusion</u></p><p>A 50 mg/ml concentration of Daptomycin for infusion is obtained by reconstituting the lyophilised product with 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.</p><p>The lyophilised product takes approximately 15 minutes to dissolve. The fully reconstituted product will appear clear and may have a few small bubbles or foam around the edge of the vial.</p><p>To prepare Daptomycin for intravenous infusion, please adhere to the following instructions:</p><p>Aseptic technique should be used throughout to reconstitute lyophilised Daptomycin.</p><p>1. The polypropylene flip off cap should be removed to expose the central portions of the rubber stopper. Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to dry. After cleaning, do not touch the rubber stopper or allow it to touch any other surface. Draw 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection into a syringe using a sterile transfer needle that is 21 gauge or smaller in diameter, or a needleless device, then slowly inject through the centre of the rubber stopper into the vial pointing the needle towards the wall of the vial.</p><p>2. The vial should be gently rotated to ensure complete wetting of the product and then allowed to stand for 10 minutes.</p><p>3. Finally the vial should be gently rotated/swirled for a few minutes as needed to obtain a clear reconstituted solution. Vigorous shaking/agitation should be avoided to prevent foaming of the product.</p><p>4. The reconstituted solution should be checked carefully to ensure that the product is in solution and visually inspected for the absence of particulates prior to use. Reconstituted solutions of Daptomycin range in colour from pale yellow to light brown.</p><p>5. Slowly remove the reconstituted liquid (50 mg daptomycin/ml) from the vial using a sterile needle that is 21 gauge or smaller in diameter and a new syringe; as described in step 6.</p><p>6. Invert the vial in order to allow the solution to drain towards the stopper. Using the new syringe, insert the needle into the inverted vial. Keeping the vial inverted, position the needle tip at the very bottom of the solution in the vial when drawing the solution into the syringe. Before removing the needle from the vial, pull the plunger all the way back to the end of the syringe barrel in order to remove all of the solution from the inverted vial.</p><p>7. The reconstituted solution should then be diluted with sodium chloride 9 mg/ml (0.9%) (typical volume 50 ml).</p><p>8. If to be administrated from the syringe, replace needle with a new needle for the intravenous infusion.</p><p>9. Expel air, large bubbles, and any excess solution in order to obtain the required dose.</p><p>10. The reconstituted and diluted solution should then be infused intravenously over 30 or 60 minutes as directed in section 4.2.</p><p>The following have been shown to be compatible when added to daptomycin containing infusion solutions:</p><p>aztreonam, ceftazidime, ceftriaxone, gentamicin, fluconazole, levofloxacin, dopamine, heparin and</p><p>lidocaine. Daptomycin</p><p>&nbsp;</p><p><u>Daptomycin given as 2 -minute intravenous injection</u></p><p>Water should not be used for reconstitution of Daptomycin for intravenous injection. Daptomycin should only be reconstituted with sodium chloride 9 mg/ml (0.9%).</p><p>A 50 mg/ml concentration of Daptomycin for injection is obtained by reconstituting the lyophilised product with 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection.</p><p>The lyophilised product takes approximately 15 minutes to dissolve. The fully reconstituted product will appear clear and may have a few small bubbles or foam around the edge of the vial.</p><p>To prepare Daptomycin for intravenous injection, please adhere to the following instructions:</p><p>Aseptic technique should be used throughout to reconstitute lyophilised Daptomycin.</p><p>1. The polypropylene flip off cap should be removed to expose the central portions of the rubber stopper. Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to dry. After cleaning, do not touch the rubber stopper or allow it to touch any other surface. Draw 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection into a syringe using a sterile transfer needle that is 21 gauge or smaller in diameter, or a needleless device, then slowly inject through the centre of the rubber stopper into the vial pointing the needle towards the wall of the vial.</p><p>2. The vial should be gently rotated to ensure complete wetting of the product and then allowed to stand for 10 minutes.</p><p>3. Finally the vial should be gently rotated/swirled for a few minutes as needed to obtain a clear reconstituted solution. Vigorous shaking/agitation should be avoided to prevent foaming of the product.</p><p>4. The reconstituted solution should be checked carefully to ensure that the product is in solution and visually inspected for the absence of particulates prior to use. Reconstituted solutions of Daptomycin range in colour from pale yellow to light brown.</p><p>5. Slowly remove the reconstituted liquid (50 mg daptomycin/ml) from the vial using a sterile needle that is 21 gauge or smaller in diameter and a new syringe; as described in step 6.</p><p>6. Invert the vial in order to allow the solution to drain towards the stopper. Using a new syringe, insert the needle into the inverted vial. Keeping the vial inverted, position the needle tip at the very bottom of the solution in the vial when drawing the solution into the syringe. Before removing the needle from the vial, pull the plunger all the way back to the end of the syringe barrel in order to remove all of the solution from the inverted vial.</p><p>7. Replace needle with a new needle for the intravenous injection.</p><p>8. Expel air, large bubbles, and any excess solution in order to obtain the required dose.</p><p>9. The reconstituted solution should then be injected intravenously slowly over 2 minutes as directed in section 4.2.</p><p>Daptomycin vials are for single-use only.</p><p>From a microbiological point of view, the product should be used immediately after reconstitution (see section 6.3). Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jul-2019
SPC-022-00

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>